'Stealth' nanoparticles make Chagas med more effective

South America

A study published in the American Society for Microbiology’s journal has shown that a new “stealth” nanoparticle cured more than half of mice infected by the deadly Chagas disease parasite, a particular concern for Latin American countries.

A team led by Marta de Lana of Brazil’s Federal University of Ouro Preto designed nanocapsules as a vehicle for lychnopholide, a plant extract known for its ability to kill the parasite Trypanosome cruzi, which causes Chagas disease. Nanocapsules had been used previously to deliver the treatment, but they are attacked by the body’s immune cells, decreasing the effectiveness.

The new capsules, on the other hand, go unrecognized by the immune system and are able to enter host cells and kill the parasite without detection. What’s more, the particles’ design allows them to make it past the acids and enzymes of the stomach, so the treatment can be administered orally as opposed to intravenously like other Chagas meds. Because of the disease’s spread in developing countries, an oral option would be more practical.

Free Webinar

Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!

In early stages of the disease, the stealth nanoparticles cured 62.5% of mice compared to 57% with the conventional ones. And in later stages, the stealth particles cured 55.6% to 30%, respectively.

"Chagas disease affects millions of people, mainly in poor rural areas of 21 Latin American countries," de Lana said. "Both nanoencapsulated formulations are so simple that they may be produced in a simple laboratory.”

- here's the release

Related Article:
Biomarkers could change the course of Chagas' disease treatment

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.